Atria Wealth Solutions Inc. Invests $412,000 in United Therapeutics Co. (NASDAQ:UTHR)

Atria Wealth Solutions Inc. bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,169 shares of the biotechnology company’s stock, valued at approximately $412,000.

A number of other large investors have also added to or reduced their stakes in the business. Creative Planning raised its position in shares of United Therapeutics by 8.9% in the third quarter. Creative Planning now owns 3,935 shares of the biotechnology company’s stock valued at $1,410,000 after purchasing an additional 322 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in United Therapeutics by 82.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,874 shares of the biotechnology company’s stock valued at $1,747,000 after acquiring an additional 2,208 shares during the period. Nisa Investment Advisors LLC lifted its position in United Therapeutics by 4.0% during the third quarter. Nisa Investment Advisors LLC now owns 22,779 shares of the biotechnology company’s stock worth $8,163,000 after acquiring an additional 870 shares during the last quarter. Pallas Capital Advisors LLC lifted its position in United Therapeutics by 62.5% during the third quarter. Pallas Capital Advisors LLC now owns 1,895 shares of the biotechnology company’s stock worth $664,000 after acquiring an additional 729 shares during the last quarter. Finally, New York State Teachers Retirement System boosted its holdings in shares of United Therapeutics by 6.5% during the third quarter. New York State Teachers Retirement System now owns 59,411 shares of the biotechnology company’s stock worth $21,290,000 after acquiring an additional 3,607 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 124,164 shares of company stock valued at $45,278,893. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $323.62 on Friday. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The stock has a market capitalization of $14.45 billion, a price-to-earnings ratio of 14.21, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The company’s 50 day simple moving average is $360.44 and its 200 day simple moving average is $360.55.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the firm earned $4.36 EPS. As a group, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on UTHR. Argus lifted their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.